 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
New P1/2 trial, Combination therapy, Metastases: A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Jul 31, 2024
P1/2, N=280, Not yet recruiting, Sponsor: Akeso
- | lancastotug (AK127) / Akesobio, Kaitanni (cadonilimab) / Akesobio
Phase classification, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - Mar 25, 2024
P1, N=143, Recruiting, Sponsor: Akesobio Australia Pty Ltd
Phase classification: P1a/1b --> P1
- ||| lancastotug (AK127) / Akesobio, Kaitanni (cadonilimab) / Akesobio
Enrollment open, Combination therapy, Metastases: A Phase Ia/Ib Open Label?Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - Sep 21, 2023
P1a/1b, N=205, Recruiting, Sponsor: Akeso
Phase classification: P1a/1b --> P1 Not yet recruiting --> Recruiting
- ||||| lancastotug (AK127) / Akesobio, Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
New P1/2 trial, Combination therapy, Metastases: A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 20, 2023
P1/2, N=216, Not yet recruiting, Sponsor: Akeso
- ||| lancastotug (AK127) / Akesobio, Kaitanni (cadonilimab) / Akesobio
New P1 trial, Combination therapy, Metastases: A Phase Ia/Ib Open Label?Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - May 22, 2023
P1a/1b, N=205, Not yet recruiting, Sponsor: Akeso
- ||| lancastotug (AK127) / Akesobio, Kaitanni (cadonilimab) / Akesobio
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - Jan 9, 2023
P1a/1b, N=143, Recruiting, Sponsor: Akesobio Australia Pty Ltd
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: May 2023 --> Apr 2025 | Trial primary completion date: Mar 2023 --> Jan 2025
- || lancastotug (AK127) / Akesobio
New P1 trial, Monotherapy, Metastases: A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 26, 2022
P1, N=36, Not yet recruiting, Sponsor: Akeso
- ||| lancastotug (AK127) / Akesobio, Kaitanni (cadonilimab) / Akesobio
New P1 trial, Combination therapy, Metastases: A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - Aug 24, 2021
P1a/1b, N=143, Not yet recruiting, Sponsor: Akeso